- Will Represent Watson's 12th Generic Product Launch in 2003 -
CORONA, Calif., Sept. 8 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that it has received final approval from the United States Food and Drug
Administration on its Abbreviated New Drug Application for Oxycodone and
Acetaminophen (APAP) tablets in 7.5mg/325mg and 10mg/325mg strengths.
Oxycodone/APAP is the generic equivalent to Endo Pharmaceuticals' Percocet(R)
tablets and is indicated for the relief of moderate to moderately severe pain.
For the 12-months ending June 2003, Percocet(R) 7.5mg/325mg and 10mg/325mg had
sales of approximately $142 million.
(Logo: http://www.newscom.com/cgi-bin/prnh/20020214/WATSONLOGO )
The Company expects a full launch by late 2003 and timing is dependent on
obtaining quota from the Drug Enforcement Administration, adequate supply of
active ingredient, and build-up of launch quantities.
About Watson Pharmaceuticals, Inc.
Watson Pharmaceuticals, Inc., headquartered in Corona, CA, is a leading
specialty pharmaceutical company that develops, manufactures, markets and
distributes branded and generic pharmaceutical products. Watson pursues a
growth strategy combining internal product development, strategic alliances
and collaborations and synergistic acquisitions of products and businesses.
For press releases and other company information, visit Watson
Pharmaceuticals' Web site at http://www.watsonpharm.com .
Forward-Looking Statement
Any statements contained in this press release that refer to future events
or other non-historical facts are forward-looking statements that reflect
Watson's current perspective of existing trends and information as of the date
of this release. Except as expressly required by law, Watson disclaims any
intent or obligation to update these forward-looking statements. Actual
results may differ materially from Watson's current expectations depending
upon a number of factors affecting Watson's business. These factors include,
among others, risks and uncertainties detailed in Watson's periodic public
filings with the Securities and Exchange Commission, including but not limited
to Watson's Annual Report on Form 10-K for the year ended December 31, 2002
and its Quarterly Report on Form 10-Q for the quarters ended March 31 and June
30, 2003.
Percocet(R) is a registered trademark of Endo Pharmaceuticals, Inc.
SOURCE Watson Pharmaceuticals, Inc.
 back to top
Related links:
http://www.watsonpharm.com
Photo Notes:
NewsCom:
http://www.newscom.com/cgi-bin/prnh/20020214/WATSONLOGO
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, photodesk@prnewswire.com
CONTACT:
investors, Patty Eisenhaur, +1-909-493-5611,
or media, Chris Eso +1-909-493-4013, both of Watson
Pharmaceuticals, Inc.
|
